Your browser doesn't support javascript.
loading
The somatic genomic landscape of chromophobe renal cell carcinoma.
Davis, Caleb F; Ricketts, Christopher J; Wang, Min; Yang, Lixing; Cherniack, Andrew D; Shen, Hui; Buhay, Christian; Kang, Hyojin; Kim, Sang Cheol; Fahey, Catherine C; Hacker, Kathryn E; Bhanot, Gyan; Gordenin, Dmitry A; Chu, Andy; Gunaratne, Preethi H; Biehl, Michael; Seth, Sahil; Kaipparettu, Benny A; Bristow, Christopher A; Donehower, Lawrence A; Wallen, Eric M; Smith, Angela B; Tickoo, Satish K; Tamboli, Pheroze; Reuter, Victor; Schmidt, Laura S; Hsieh, James J; Choueiri, Toni K; Hakimi, A Ari; Chin, Lynda; Meyerson, Matthew; Kucherlapati, Raju; Park, Woong-Yang; Robertson, A Gordon; Laird, Peter W; Henske, Elizabeth P; Kwiatkowski, David J; Park, Peter J; Morgan, Margaret; Shuch, Brian; Muzny, Donna; Wheeler, David A; Linehan, W Marston; Gibbs, Richard A; Rathmell, W Kimryn; Creighton, Chad J.
Afiliación
  • Davis CF; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Ricketts CJ; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, MD 20892, USA.
  • Wang M; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Yang L; Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
  • Cherniack AD; The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
  • Shen H; USC Epigenome Center, University of Southern California, Los Angeles, CA 90033, USA.
  • Buhay C; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Kang H; National Institute of Supercomputing and Networking, Korea Institute of Science and Technology Information, Daejeon, Korea.
  • Kim SC; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
  • Fahey CC; Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Hacker KE; Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Bhanot G; Department of Molecular Biology and Biochemistry, Rutgers University, Busch Campus, Piscataway, NJ 08854, USA; Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA.
  • Gordenin DA; National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA.
  • Chu A; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver BC V5Z 4S6, Canada.
  • Gunaratne PH; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Biology & Biochemistry, University of Houston, 4800 Calhoun Road, Houston, TX 77204, USA.
  • Biehl M; Johann Bernoulli Institute for Mathematics and Computer Science, Intelligent Systems Group, University of Groningen, P.O. Box 407, 9700 AK Groningen, the Netherlands.
  • Seth S; Department of Genomic Medicine, Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kaipparettu BA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Bristow CA; Department of Genomic Medicine, Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Donehower LA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Wallen EM; Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Smith AB; Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Tickoo SK; Department of Pathology, Memorial Sloan-Kettering Cancer, 1275 York Avenue, New York, NY 10065, USA.
  • Tamboli P; Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
  • Reuter V; Department of Pathology, Memorial Sloan-Kettering Cancer, 1275 York Avenue, New York, NY 10065, USA.
  • Schmidt LS; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, MD 20892, USA; Leidos Biomedical Research, Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • Hsieh JJ; Department of Medicine, Weill-Cornell Medical College, New York, NY 10021, USA; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
  • Hakimi AA; Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • Chin L; The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Genomic Medicine, Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Meyerson M; The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
  • Kucherlapati R; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Park WY; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Robertson AG; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver BC V5Z 4S6, Canada.
  • Laird PW; USC Epigenome Center, University of Southern California, Los Angeles, CA 90033, USA.
  • Henske EP; The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02215
  • Kwiatkowski DJ; The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02215
  • Park PJ; Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • Morgan M; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Shuch B; Department of Urology, Yale School of Medicine, New Haven, CT 06520, USA.
  • Muzny D; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Wheeler DA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC Room 1W-5940, Bethesda, MD 20892, USA.
  • Gibbs RA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Rathmell WK; Department of Urology, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. Ele
  • Creighton CJ; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: creighto@bcm.edu.
Cancer Cell ; 26(3): 319-330, 2014 Sep 08.
Article en En | MEDLINE | ID: mdl-25155756
We describe the landscape of somatic genomic alterations of 66 chromophobe renal cell carcinomas (ChRCCs) on the basis of multidimensional and comprehensive characterization, including mtDNA and whole-genome sequencing. The result is consistent that ChRCC originates from the distal nephron compared with other kidney cancers with more proximal origins. Combined mtDNA and gene expression analysis implicates changes in mitochondrial function as a component of the disease biology, while suggesting alternative roles for mtDNA mutations in cancers relying on oxidative phosphorylation. Genomic rearrangements lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly elevated TERT expression and manifestation of kataegis, representing a mechanism of TERT upregulation in cancer distinct from previously observed amplifications and point mutations.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos